MD Biosciences

MD Biosciences is a Healthcare company based in Zurich (Switzerland) founded in 1991, and was acquired by MLM in October 2020. CRO developing drugs and offering preclinical, assay development and clinical services. MD Biosciences offers products and services including Cell-based Assays, Efficacy Assessments, PK/PD & Toxicology, Biomarker Analysis, and Histology. Its focus areas include Biopharma Outsourcing, CRO, Diversified and Diversified Pharmaceuticals.

Company details

MD Biosciences is a niche preclincial and clincial research company. Their core therapeutic areas are inflammation, neurology, CNS, pain and cardiovascular with an emphasis on the interplay between these systems. The company has four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. The company offers the following services - Biomarker Studies, Cell Based Assays, HistologyIHC, Model Development, PharmacologyEfficacy Models, Phenotypic Screening. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora. The company is developing a pipeline of compounds - MD 354 (non-opioid treatment for neuropathic and chronic pain), MD 22 (anti-inflammatory to treat lower back pain), MD 401B (vectorized vaccine for the canine osteocarcinoma), MD 401A (vectorized vaccine for the human osteocarcinoma), MD 402 (undisclosed treatment of cancer). Most of these candidates are in preclinical development and are available for partnering and out-licensing. Finally, MD Bioproducts is a division of MD Biosciences and also offers products (reagents and assays) for use in the inflammations, neurology, endocrinology, and metabolic disorders research fields.